Sponsors (12)
The legislation would restrict FDA‑approved medication abortion—an outcome valued by anti‑abortion constituencies—but would substantially reduce access to noninvasive abortion care and create significant health, economic, legal, and supply‑chain harms for patients, providers, and public programs.
Anti‑abortion Americans and advocacy groups would see reduced availability of medication abortion (including mifepristone), aligning law and practice with their preference to restrict abortion access.
State governments and lawmakers seeking to limit abortion would gain a clearer legal basis to challenge or restrict FDA‑approved medication abortions, which they may view as reasserting legislative control over drug approvals for pregnancy.
Some Americans who oppose abortion could see an increase in births (relative to current medication‑abortion availability), which they consider a social or moral benefit.
Pregnant people seeking abortion would lose access to FDA‑approved medication abortion (including mifepristone), forcing many to pursue surgical procedures or unapproved alternatives and reducing timely, noninvasive care.
Patients—especially low‑income individuals—would face higher out‑of‑pocket costs and reduced treatment options if medication abortion is unavailable, increasing reliance on costlier surgical care and potentially delaying care.
Medicaid beneficiaries and state/federal public‑health programs would likely incur higher costs from increased pregnancy‑related care, complications, and longer hospital stays if medication abortion access is restricted.
Based on analysis of 2 sections of legislative text.
Bars HHS/FDA from treating pregnancy as an illness for abortion-drug approvals or REMS and voids prior approvals that relied on that rationale, including the standing mifepristone approval.
Prohibits the Department of Health and Human Services (including the FDA) from treating pregnancy as an illness when approving abortion drugs or when imposing or maintaining Risk Evaluation and Mitigation Strategies (REMS). It also voids, from the start, any existing FDA approvals that relied in whole or in part on treating pregnancy as an illness — explicitly including the FDA approval of mifepristone that was in effect the day before this law takes effect. The law takes effect on enactment and would remove approvals and any related REMS that used that rationale.
Introduced January 28, 2025 by Mary E. Miller · Last progress January 28, 2025